Phylogica IPO closes oversubscribed
Thursday, 24 March, 2005
Perth-based functional proteomics company Phylogica has closed its IPO after raising $5 million through the sale of 25 million shares at $0.20.
Although the IPO was heavily oversubscribed, no oversubscriptions were accepted.
Major investors in the float include listed investment group Biotech Capital (ASX:BTC) and the Australian Heritage Group. Azure Capital managed the IPO.
The company was spun out of the Telethon Institute for Child Health Research to commercialise technology developed by researchers at the institute and their collaborators at Fox Chase Cancer Center in the US.
The company is expected to float on the ASX at 10:30am on March 30, 2005, using the code PYC.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
